# National Vision Holdings, Inc.: financial statements, quarterly

EYE · Nasdaq · CIK 1710155 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jan 2

Pages: [Overview](/companies/eye.md) · [Financials](/companies/eye/financials.md) · [Filings](/companies/eye/filings.md) · [Insiders](/companies/eye/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/eye/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q4 FY2025 (2026-01-03) | Q1 FY2026 (2026-04-04) | Q2 FY2026 (2026-07-04) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [439](/filings/0001710155-25-000011.md) | [421](/filings/0001710155-25-000011.md) | [483](/filings/0001710155-25-000022.md) | [452](/filings/0001710155-25-000047.md) | [452](/filings/0001628280-25-049891.md) | [437](/filings/0001710155-25-000011.md) | [510](/filings/0001628280-26-034824.md) | [486](/filings/0001628280-26-056493.md) | [487](/filings/0001628280-25-049891.md) | [503 d](/filings/0001628280-26-014379.md) | [544](/filings/0001628280-26-034824.md) | [499](/filings/0001628280-26-056493.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [228](/filings/0001710155-24-000060.md) | [226 d](/filings/0001628280-26-014379.md) | [240](/filings/0001710155-25-000022.md) | [231](/filings/0001710155-25-000047.md) | [234](/filings/0001628280-25-049891.md) | [233 d](/filings/0001628280-26-014379.md) | [256](/filings/0001628280-26-034824.md) | [247](/filings/0001628280-26-056493.md) | [252](/filings/0001628280-25-049891.md) | [261 d](/filings/0001628280-26-014379.md) | [256](/filings/0001628280-26-034824.md) | [243](/filings/0001628280-26-056493.md) |
| Operating income | $m | [3.5](/filings/0001710155-25-000011.md) | [(12.4)](/filings/0001710155-25-000011.md) | [23.4](/filings/0001710155-25-000022.md) | [0.6](/filings/0001710155-25-000047.md) | [(8.8)](/filings/0001628280-25-049891.md) | [(25.6)](/filings/0001710155-25-000011.md) | [26.1](/filings/0001628280-26-034824.md) | [16.4](/filings/0001628280-26-056493.md) | [9.6](/filings/0001628280-25-049891.md) | [6.6 d](/filings/0001628280-26-014379.md) | [45.2](/filings/0001628280-26-034824.md) | [21.3](/filings/0001628280-26-056493.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.2](/filings/0001710155-24-000060.md) | [(2.2) d](/filings/0001628280-26-014379.md) | [7.4](/filings/0001710155-25-000022.md) | [(1.6)](/filings/0001710155-25-000047.md) | [(3.6)](/filings/0001628280-25-049891.md) | [(0.8) d](/filings/0001628280-26-014379.md) | [7.4](/filings/0001628280-26-034824.md) | [3.5](/filings/0001628280-26-056493.md) | [2.1](/filings/0001628280-25-049891.md) | [(0.9) d](/filings/0001628280-26-014379.md) | [11.2](/filings/0001628280-26-034824.md) | [5.5](/filings/0001628280-26-056493.md) |
| Net income | $m | [(73.8)](/filings/0001710155-25-000011.md) | [(16.0)](/filings/0001710155-25-000011.md) | [11.7](/filings/0001628280-25-049891.md) | [(3.1)](/filings/0001628280-25-049891.md) | [(8.5)](/filings/0001628280-25-049891.md) | [(28.6)](/filings/0001710155-25-000011.md) | [14.2](/filings/0001628280-26-056493.md) | [8.7](/filings/0001628280-26-056493.md) | [3.4](/filings/0001628280-25-049891.md) | [3.3 d](/filings/0001628280-26-014379.md) | [31.2](/filings/0001628280-26-056493.md) | [12.4](/filings/0001628280-26-056493.md) |
| Diluted EPS | $ per share | [(0.94)](/filings/0001710155-25-000011.md) | [(0.20)](/filings/0001710155-25-000011.md) | [0.15](/filings/0001710155-25-000022.md) | [(0.04)](/filings/0001710155-25-000047.md) | [(0.11)](/filings/0001628280-25-049891.md) | [(0.36)](/filings/0001710155-25-000011.md) | [0.18](/filings/0001628280-26-034824.md) | [0.11](/filings/0001628280-26-056493.md) | [0.04](/filings/0001628280-25-049891.md) | not reported | [0.38](/filings/0001628280-26-034824.md) | [0.15](/filings/0001628280-26-056493.md) |
| Basic EPS | $ per share | [(0.94)](/filings/0001710155-25-000011.md) | [(0.20)](/filings/0001710155-25-000011.md) | [0.15](/filings/0001710155-25-000022.md) | [(0.04)](/filings/0001710155-25-000047.md) | [(0.11)](/filings/0001628280-25-049891.md) | [(0.36)](/filings/0001710155-25-000011.md) | [0.18](/filings/0001628280-26-034824.md) | [0.11](/filings/0001628280-26-056493.md) | [0.04](/filings/0001628280-25-049891.md) | not reported | [0.39](/filings/0001628280-26-034824.md) | [0.16](/filings/0001628280-26-056493.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | FY2024 (2024-12-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | FY2025 (2026-01-03) | Q1 FY2026 (2026-04-04) | Q2 FY2026 (2026-07-04) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [266](/filings/0001710155-24-000060.md) | [150](/filings/0001628280-26-014379.md) | [150](/filings/0001710155-25-000022.md) | [180](/filings/0001710155-25-000047.md) | [81.2](/filings/0001628280-25-049891.md) | [73.9](/filings/0001628280-26-014379.md) | [80.0](/filings/0001628280-26-034824.md) | [48.5](/filings/0001628280-26-056493.md) | [56.0](/filings/0001628280-25-049891.md) | [38.7](/filings/0001628280-26-056493.md) | [67.9](/filings/0001628280-26-034824.md) | [36.0](/filings/0001628280-26-056493.md) |
| Current assets | $m | [500](/filings/0001710155-23-000052.md) | [397](/filings/0001710155-25-000011.md) | [379](/filings/0001710155-24-000028.md) | [364](/filings/0001710155-24-000052.md) | [244](/filings/0001710155-24-000060.md) | [250](/filings/0001628280-26-014379.md) | [254](/filings/0001710155-25-000022.md) | [218](/filings/0001710155-25-000047.md) | [220](/filings/0001628280-25-049891.md) | [226](/filings/0001628280-26-056493.md) | [261](/filings/0001628280-26-034824.md) | [227](/filings/0001628280-26-056493.md) |
| Total assets | $m | [2,266](/filings/0001710155-23-000052.md) | [2,173](/filings/0001710155-25-000011.md) | [2,155](/filings/0001710155-24-000028.md) | [2,146](/filings/0001710155-24-000052.md) | [2,020](/filings/0001710155-24-000060.md) | [2,008](/filings/0001628280-26-014379.md) | [2,010](/filings/0001710155-25-000022.md) | [1,968](/filings/0001710155-25-000047.md) | [1,958](/filings/0001628280-25-049891.md) | [1,984](/filings/0001628280-26-056493.md) | [2,020](/filings/0001628280-26-034824.md) | [1,983](/filings/0001628280-26-056493.md) |
| Current liabilities | $m | [374](/filings/0001710155-23-000052.md) | [398](/filings/0001710155-25-000011.md) | [375](/filings/0001710155-24-000028.md) | [663](/filings/0001710155-24-000052.md) | [426](/filings/0001710155-24-000060.md) | [468](/filings/0001628280-26-014379.md) | [468](/filings/0001710155-25-000022.md) | [418](/filings/0001710155-25-000047.md) | [417](/filings/0001628280-25-049891.md) | [412](/filings/0001628280-26-056493.md) | [418](/filings/0001628280-26-034824.md) | [383](/filings/0001628280-26-056493.md) |
| Long-term debt | $m | [538](/filings/0001710155-23-000052.md) | [438](/filings/0001710155-25-000011.md) | [436](/filings/0001710155-24-000028.md) | [132](/filings/0001710155-24-000052.md) | [242](/filings/0001710155-24-000060.md) | [239](/filings/0001628280-26-014379.md) | [236](/filings/0001710155-25-000022.md) | [248](/filings/0001710155-25-000047.md) | [230](/filings/0001628280-25-049891.md) | [223](/filings/0001628280-26-056493.md) | [220](/filings/0001628280-26-034824.md) | [217](/filings/0001628280-26-056493.md) |
| Current portion of debt | $m | [7.5](/filings/0001710155-23-000052.md) | [7.5](/filings/0001710155-25-000011.md) | [7.5](/filings/0001710155-24-000028.md) | [310](/filings/0001710155-24-000052.md) | [98.0](/filings/0001710155-24-000060.md) | [98.0](/filings/0001628280-26-014379.md) | [98.0](/filings/0001710155-25-000022.md) | [13.3](/filings/0001710155-25-000047.md) | [13.3](/filings/0001628280-25-049891.md) | [13.3](/filings/0001628280-26-056493.md) | [13.3](/filings/0001628280-26-034824.md) | [13.3](/filings/0001628280-26-056493.md) |
| Shareholders' equity | $m | [840](/filings/0001710155-24-000060.md) | [829](/filings/0001628280-26-014379.md) | [841](/filings/0001628280-25-049891.md) | [843](/filings/0001628280-25-049891.md) | [840](/filings/0001628280-25-049891.md) | [816](/filings/0001628280-26-056493.md) | [836](/filings/0001628280-26-056493.md) | [851](/filings/0001628280-26-056493.md) | [859](/filings/0001628280-25-049891.md) | [870](/filings/0001628280-26-056493.md) | [898](/filings/0001628280-26-056493.md) | [897](/filings/0001628280-26-056493.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q4 FY2025 (2026-01-03) | Q1 FY2026 (2026-04-04) | Q2 FY2026 (2026-07-04) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [41.1 d](/filings/0001710155-24-000060.md) | [19.8 d](/filings/0001628280-26-014379.md) | [24.0](/filings/0001710155-25-000022.md) | [51.5 d](/filings/0001710155-25-000047.md) | [27.9 d](/filings/0001628280-25-049891.md) | [30.3 d](/filings/0001628280-26-014379.md) | [32.2](/filings/0001628280-26-034824.md) | [54.3 d](/filings/0001628280-26-056493.md) | [46.6 d](/filings/0001628280-25-049891.md) | [13.2 d](/filings/0001628280-26-014379.md) | [61.7](/filings/0001628280-26-034824.md) | [8.1 d](/filings/0001628280-26-056493.md) |
| Capital expenditure | $m | [27.8 d](/filings/0001710155-24-000060.md) | [32.8 d](/filings/0001628280-26-014379.md) | [20.0](/filings/0001710155-25-000022.md) | [19.6 d](/filings/0001710155-25-000047.md) | [23.9 d](/filings/0001628280-25-049891.md) | [32.0 d](/filings/0001628280-26-014379.md) | [20.2](/filings/0001628280-26-034824.md) | [11.9 d](/filings/0001628280-26-056493.md) | [16.4 d](/filings/0001628280-25-049891.md) | [24.4 d](/filings/0001628280-26-014379.md) | [17.6](/filings/0001628280-26-034824.md) | [22.2 d](/filings/0001628280-26-056493.md) |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | [0.1 d](/filings/0001710155-24-000060.md) | [0.8 d](/filings/0001628280-26-014379.md) | [2.7](/filings/0001710155-25-000022.md) | [0.1 d](/filings/0001710155-25-000047.md) | [0.0 d](/filings/0001628280-25-049891.md) | [0.3 d](/filings/0001628280-26-014379.md) | [1.6](/filings/0001628280-26-034824.md) | [0.1 d](/filings/0001628280-26-056493.md) | [0.9 d](/filings/0001628280-25-049891.md) | [0.7 d](/filings/0001628280-26-014379.md) | [10.5](/filings/0001628280-26-034824.md) | [20.1 d](/filings/0001628280-26-056493.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: not reported
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q2 FY2023 (2023-07-01) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q1 FY2026 (2026-04-04) | Q2 FY2026 (2026-07-04) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [78.3](/filings/0001710155-25-000011.md) | [78.2](/filings/0001710155-25-000011.md) | [78.3](/filings/0001710155-25-000011.md) | [78.8](/filings/0001710155-25-000022.md) | [78.6](/filings/0001710155-25-000047.md) | [78.7](/filings/0001628280-25-049891.md) | [78.8](/filings/0001710155-25-000011.md) | [79.3](/filings/0001628280-26-034824.md) | [80.1](/filings/0001628280-26-056493.md) | [81.2](/filings/0001628280-25-049891.md) | [81.5](/filings/0001628280-26-034824.md) | [80.6](/filings/0001628280-26-056493.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 79,069,313 at 2026-07-31, from the cover of the [10-Q filed 2026-08-13](/filings/0001628280-26-056493.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.